ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO172

Serum Albumin Concentration, Estimated Glomerular Filtration Rate, and Cardiovascular Mortality among 1999-2010 NHANES Participants

Session Information

Category: Nutrition, Inflammation, and Metabolism

  • 1401 Nutrition, Inflammation, Metabolism


  • Tortorici, Amanda R., UC Irvine, Orange, California, United States
  • Streja, Elani, UC Irvine, Orange, California, United States
  • Soohoo, Melissa, UC Irvine, Orange, California, United States
  • Gillen, Daniel L., UC Irvine, Orange, California, United States
  • Rhee, Connie, UC Irvine, Orange, California, United States
  • Norris, Keith C., UCLA, Los Angeles, California, United States
  • Kalantar-Zadeh, Kamyar, UC Irvine, Orange, California, United States

As a potential strong predictor of longevity in persons with chronic kidney disease, we sought to examine whether higher serum albumin (Alb) levels are associated with reduced cardiovascular mortality in a nationally representative cohort of NHANES participants.


We identified 31,274 participants from the 1999-2010 continuous NHANES survey who had available Alb measurements and laboratory values for calculation of eGFR, as well as cardiovascular mortality data. Follow up time began the day after Alb measurement until December 31, 2011. We analyzed the association of Alb (<4.2, 4.2-<4.4 and ≥4.4 g/dL) with cardiovascular mortality across strata of eGFR (<60, 60-<90, and ≥90 ml/min/1.73m2) using Cox proportional hazards models adjusted for age, sex, race, smoking, diabetes and education.


The mean±SD age of the cohort was 48±20 years, among whom 52% were female, 20% were African-American, 22% were Mexican-American, and 7% were other Hispanic American. Across all eGFR strata, participants with Alb levels <4.2 g/dL (n=11,384 people) trended towards higher cardiovascular mortality risks compared to the reference group (Alb 4.2-<4.4 g/dL, n=10,793 people). When stratified by eGFR, participants with Alb levels >4.4 g/dL (n=9,097 overall) trended toward better cardiovascular survival among those with eGFR >60 ml/min/1.73m2 (n=8,779), but worse cardiovascular mortality among those with eGFR <60 ml/min/1.73m2 (n=318). [Figure]


Among 1999-2010 continuous NHANES participants, lower Alb levels trended toward 30% to 50% higher cardiovascular mortality risk irrespective of the eGFR level. Mortality predictability of Alb and the implications of its screening across the population at large warrants comparison to a lipid panel screening.



  • NIDDK Support